Literature DB >> 25008478

The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis.

Anders Lasson1, Per-Ove Stotzer2, Lena Öhman3, Stefan Isaksson4, Maria Sapnara5, Hans Strid2.   

Abstract

BACKGROUND AND AIMS: Leukocyte-derived proteins in faeces, especially calprotectin, are increasingly used to assess disease activity in ulcerative colitis. The objectives of the present study were to assess the importance of factors related to the stool sampling procedure.
METHODS: For 2 days, patients with active ulcerative colitis collected two stool samples at each bowel movement. The time of defecation, consistency and presence of blood were self-recorded in a diary. The variability in the concentrations of calprotectin during the day and between two consecutive days was assessed, as was the stability of calprotectin concentrations in samples stored at room temperature.
RESULTS: Altogether, 18 patients collected 287 stool samples. The intraclass correlation coefficient in pairs of samples from 132 bowel movements was 0.79 (95% CI 0.48-0.90). The median individual coefficient of variation in samples collected during the same day was 52% (4-178). There was a correlation between the level of calprotectin and the time between bowel movements (r = 0.5; p = 0.013). After 3 days at room temperature the calprotectin concentrations in stool samples were unchanged, but after 7 days a significant (p < 0.01) decrease was found (mean 28%; 95% CI 0.10-0.47).
CONCLUSION: The present data reveal a great variability in the concentrations of calprotectin in stool samples collected during a single day. Since the levels of calprotectin increased with longer time between the bowel movements, it seems most appropriate to analyse stool from the first bowel movement in the morning. Moreover, storage of stool samples at room temperature for more than 3 days is not advisable.
Copyright © 2014 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Calprotectin; Disease activity; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 25008478     DOI: 10.1016/j.crohns.2014.06.002

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  48 in total

1.  Fecal calprotectin evaluation in patients with ulcerative colitis.

Authors:  Tolga Dogan; Mehmet Agilli
Journal:  Dig Dis Sci       Date:  2015-01-14       Impact factor: 3.199

Review 2.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

Review 3.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 4.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

5.  Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study.

Authors:  Takayuki Yamamoto; Takahiro Shimoyama; Satoru Umegae; Koichi Matsumoto
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

6.  Fecal Calprotectin in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Authors:  Cong Dai; Min Jiang; Ming-Jun Sun
Journal:  Dig Dis Sci       Date:  2017-10-17       Impact factor: 3.199

Review 7.  Practical guidance on the use of faecal calprotectin.

Authors:  Matthew J Brookes; Simon Whitehead; Daniel R Gaya; Antony Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2017-02-22

Review 8.  Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease.

Authors:  Brian Bressler; Remo Panaccione; Richard N Fedorak; Ernest G Seidman
Journal:  Can J Gastroenterol Hepatol       Date:  2015-06-30

Review 9.  Probiotic supplementation in children with cystic fibrosis-a systematic review.

Authors:  Anitha Ananthan; Haribalakrishna Balasubramanian; Shripada Rao; Sanjay Patole
Journal:  Eur J Pediatr       Date:  2016-08-30       Impact factor: 3.183

Review 10.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.